Patient-Reported Outcomes of Rezvilutamide Versus Bicalutamide in Combination with Androgen Deprivation Therapy in High-Volume Metastatic Hormone-Sensitive Prostate Cancer Patients (CHART): A Randomized, Phase III Study

The randomized Phase III CHART trial revealed that rezvilutamide plus androgen deprivation therapy in high-volume, metastatic, hormone-sensitive prostate cancer significantly enhanced radiographic progression-free and overall survival than bicalutamide.